Genetic predisposition to statin myopathy

Current Opinion in Rheumatology

Volumn 20, Issue 6, 2008, Pages 648-655

  Vladutiu, Georgirene D ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b BUFFALO GENERAL HOSPITAL   (United States)

Author keywords

Carnitine palmitoyltransferase II deficiency; Coenzyme Q10; Cytochrome P 450; Genetic predisposition; McArdle disease; Muscle disease; Pharmacogenetics; Pharmacogenomics; Rhabdomyolysis; Statin myopathy

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEVINOLIN; ORGANIC ANION TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SEROTONIN RECEPTOR; SIMVASTATIN; UBIDECARENONE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; INCIDENCE; MONOTHERAPY; MUTATIONAL ANALYSIS; MYALGIA; MYOPATHY; MYOSITIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CARNITINE O-PALMITOYLTRANSFERASE; CREATINE KINASE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; PHARMACOGENETICS; RHABDOMYOLYSIS; RISK FACTORS; UBIQUINONE; UNITED STATES;

EID: 56249093499     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328314b7b4     Document Type: Review

References (52)

1. FDA News release. FDA approves updated warfarin (Coumadin) prescribing information. Rockville, Maryland: U.S. Food and Drug Administration; 16 August 2007. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01701. html. [Accessed 14 February 2008]
2. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358:999-1008.
3. Kollek R, Aken J, Feuerstein G, Schmedders M. Pharmacogenetics, adverse drug reactions and public health. Community Genet 2006; 9:50-54.
4. Ross CJ, Carleton B, Warn DG, et al. Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children. Ann N Y Acad Sci 2007; 1110:177-192.
5. Shurin SB, Nabel EG. Pharmacogenomics: ready for prime time? N Engl J Med 2008; 358:1061-1063.
6. Harper CR, Jacobsen TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007; 18:401-408.
7. Pasternak R, Smith S, Bairey-Merz C, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40:567-572.
8. Medical Expenditure Panel Survey. Agency for healthcare research and quality. http://www.meps.ahrq.gov/mepsweb/datajiles/publications/st205/stat205. pdf; 2005.
9. Ansell BJ, Fonarow GC, Maki KC, et al. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J 2006; 152:976-981.
10. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35:908-917.
11. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C-60C.
12. Graham DJ, Staffa JA, Andrade SE, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292:2585-2590.
13. Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007; 19:67-73. A thorough review of the clinical signposts, risk factors, and mechanisms of statin myopathy and an algorithm for management of the disease.
14. Christopher-Stine L. Statin myopathy: an update. Curr Opin Rheumatol 2006; 18:647-653.
15. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin Lipidol 2007; 18:409-414. A review summarizing the most recent polymorphisms in genes affecting statin pharmacodynamics and pharmacokinetics as well as muscle toxicity.
16. Schmitz G, Schmitz-Madry A, Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol 2007; 18:164-173. An up-to-date review on pharmacokinetics, genetic factors affecting lipid metabolism, and other disease-related genes with their effect on drug therapy.
17. Rodrigues AC, Hirata MH, Hirata RDC. The genetic determinants of atorvastatin response. Curr Opin Mol Ther 2007; 9:545-553.
18. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97:89-94.
19. Chan J, Hui RL, Levin E. Differential association between statin exposure and elevated levels of creatine kinase. Ann Pharmacother 2005; 39:1611-1616.
20. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev 2007; 6:904-916. A comprehensive review of genetic risk factors for serious ADRs. FDA labeling changes for drugs with genetic risk factors.
21. Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci 2008; 35:8-21. A most thorough review of statin myotoxicity as it relates to a comprehensive list of neuromuscular diseases. A clinical management algorithm is provided.
22. Phillips PS, Haas RH, Bannykh S, et al. Statin associated myopathy with normal and abnormal creatine kinase: clinical, pathological and biochemical features. Ann Intern Med 2002; 137:581-585.
23. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97:69-76.
24. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99:1409-1412.
25. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors and metabolic myopathies associated with lipid-lowering drugs. Muscle Nerve 2006; 34:153-162.
26. Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006; 210:94-102.
27. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol 2006; 97:27C-31C.
28. Capasso M, DeAngelis MV, DiMuzio A, et al. Familial idiopathic hyper-CK-emia: an under recognized condition. Muscle Nerve 2006; 33:760-765.
29. Sailler L, Pereira C, Bagheri A, et al. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis 2008; 67:614-619.
30. Pasanen MK, Fredrikson H, Neuconen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007; 82:726-733.
31. Niemi M, Pasanen MB, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006; 80:356-366.
32. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. New Engl J Med 2008; 359:789-799. The most definitive study thus far published associating a single genetic variant with dose-related statin-induced myopathy.
33. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372:432-443.
34. Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis 2007; 6:1-5. The first pharmacogenetic study of polymorphisms in the CoQ2 gene relevant to statin intolerance.
35. Ruano G, Thompson PD, Windemuth A, et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 2005; 6:865-872.
36. Ruano G, Thompson PD, Windemuth A, et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 2007; 36:329-335.
37. Frudakis TN, Thomas MJ, Ginjupalli SN, et al. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 2007; 17:695-707.
38. Haller RG. Treatment of McArdle disease. Arch Neurol 2000; 57:923-924.
39. Guis S, Figarella-Branger D, Mattel JP, et al. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arth Rheum 2006; 55:551-557.
40. Vladutiu GD. Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al. Arth Rheum 2007; 57:186-188.
41. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. J Am Coll Cardiol 2007; 49:2231-2237.
42. Kawashiri M, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008; 83:731-739.
43. Casarin A, Jimenez-Ortega JC, Trevisson E, et al. Functional characterization of human CoQ4, a gene required for Coenzyme Q10 biosynthesis. Biochem Biophys Res Commun 2008; 372:35-39.
44. Mollet J, Giurgea I, Schlemmer D, et al. Prenyldiphosphatesynthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest 2007; 117:765-772.
45. Quinzii C, Naini A, Salviati L, et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (CoQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006; 78:345-349.
46. Lopez L, Schuelke M, Quinzii CM, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 2006; 79:1125-1129.
47. Lagier-Tourenne C, Tazir M, Lopez LC, et al. ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet 2008; 82:661-672.
48. Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring- flavoprotein dehydrogenase (ETFDH) gene. Brain 2007; 130:2037-2044.
49. Date H, Onodera O, Tanaka H. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat Genet 2001; 29:184-188.
50. DiMauro S, Quinzii CM, Hirano M. Mutations in coenzymeQ10 biosynthetic genes. J Clin Invest 2007; 117:587-589.
51. Hanai J-I, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117:3940-3951. A comprehensive study of the in-vitro and in-vivo effects of statins on the function of a gene associated with muscle atrophy.
52. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-1 associated with statin therapy. Neuromuscul Disord 2007; 17:194-200.